findmyKOL

Daniel Winetsky, MD

Basic profile

SUNY Downstate Health Sciences University

ORCIDNPI
RegionBrooklyn, NY · NortheastSpecialtyInfectious DiseaseFocusInfectious Disease
Last active 2024findmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2024Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Daniel Winetsky is an Infectious Disease physician affiliated with SUNY Downstate Health Sciences University. OpenAlex indexes 19 publications with 323 citations (h-index 8).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
19publications

Distinct works indexed by OpenAlex, matched via ORCID.

323citations

Total citations across indexed works.

8h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
2companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

450 Clarkson Ave Ste J
Brooklyn, NY 112032012

Telephone

718-270-6747

Provider last certified this registry record 6 May 2022.

View the NPPES registry record

Industry payments

2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    36.8%
    Statin15.8%
    Atorvastatin Calcium57%Rosuvastatin Calcium43%
    Part D35 patients
    Calcium channel blocker5.9%
    Amlodipine Besylate76%Amlodipine-Valsartan25%
    Part D<11 patients

    + 6 more classes in this area

  • Anti-infectives

    20.9%
    Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor10%
    Juluca60%Tivicay40%
    Part D12 patients
    Protease Inhibitor5.2%
    Symtuza40%Prezcobix35%Darunavir25%
    Part D<11 patients

    + 4 more classes in this area

  • Metabolism & gastrointestinal

    15.5%
    GLP-1 receptor agonist4.7%
    Ozempic82%Trulicity18%
    Part D<11 patients
    Biguanide (metformin)4.1%
    Metformin Hcl68%Metformin Hcl Er32%
    Part D<11 patients

    + 4 more classes in this area

Where care is delivered (Part B), 2023100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”